Integer Holdings Corp (ITGR) Stock Analysis and Metrics

Integer Holdings

NYSE: ITGR

$98.73 ▲ +1.23 (+1.26%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3.34 Bn

P/S1.80

Div. Yield0.00

ROIC (Qtr)0.05

Total Debt (Qtr)1.25 Bn

Revenue Growth (1y) (Qtr)0.50

Add ratio to table…

About

Integer Holdings Corporation is a leading medical device contract development and manufacturing organization headquartered in Plano Texas. The company provides design development and manufacturing services for components subassemblies and finished devices used in the Cardio and Vascular Neuromodulation and Cardiac Rhythm Management markets. Its brands include Greatbatch Medical and Lake Region Medical. Integer Holdings Corporation focuses on delivering high quality solutions to multinational original equipment manufacturers through a global network of manufacturing sites.

Integer Holdings Corporation generates revenue by selling medical device components subassemblies and finished products to its customers. The company’s revenue comes from three principal product lines: Cardio and Vascular Cardiac Rhythm Management and Neuromodulation and Other Markets. Within these lines it offers items such as catheter based systems implantable pulse generators leads batteries and minimally invasive surgery tools. The primary customers are large multinational medical device original equipment manufacturers that purchase custom and standard parts for their own product lines.

The company operates through the following segments:

• Integer Holdings Corporation operates as a single reportable segment that encompasses its contract development and manufacturing business. This segment includes the Cardio and Vascular product line which produces components for interventional cardiology structural heart heart failure peripheral vascular neurovascular electrophysiology vascular access infusion therapy hemodialysis urology and gastroenterology procedures. It also includes the Cardiac Rhythm Management and Neuromodulation product line which supplies implantable pulse generators leads batteries device enclosures and related accessories for cardiac rhythm and neurotherapy applications. Finally the segment covers the Other Markets line which provides products for minimally invasive surgery orthopedics and portable medical equipment. All activities are supported by a global footprint of manufacturing facilities in the United States Mexico Uruguay Ireland Malaysia Costa Rica and the Dominican Republic.

Integer Holdings Corporation holds a strong position as one of the world’s largest medical device contract development and manufacturing organizations. Its competitive advantages arise from a broad technology platform that covers design engineering material processing and final assembly capabilities. The company benefits from a large installed base of manufacturing equipment a deep intellectual property portfolio that includes hundreds of patents and a reputation for quality and regulatory compliance. While the contract manufacturing industry is fragmented with many smaller players Integer Holdings Corporation differentiates itself by offering end to end solutions that range from concept development to finished device delivery and by maintaining long term relationships with major original equipment manufacturers.

The company’s customer base consists primarily of large multinational medical device original equipment manufacturers and their affiliated subsidiaries. In 2025 three customers Abbott Laboratories Boston Scientific and Medtronic each accounted for more than ten percent of total sales and together represented approximately forty nine percent of revenue. In addition to these major clients Integer Holdings Corporation serves a diverse set of other medical device companies that rely on its expertise for specific product programs across its three product focus areas.

Investment Thesis

▲ Bull case

Integer Holdings Corporation's strategic review, driven by heightened market interest, presents a significant but underappreciated catalyst for shareholder value creation that extends beyond mere speculation. Management's emphasis on maintaining confidence in their standalone strategy while exploring alternatives suggests the process could yield tangible outcomes such as a premium acquisition offer from a larger medtech player seeking to enhance its CDMO capabilities, particularly in high-growth areas like electrophysiology and neurovascular. The company's strong pipeline, deep relationships with industry leaders, and proven ability to accelerate customer timelines through engineering excellence make it an attractive target, and the Board's fiduciary duty to maximize value increases the likelihood of a favorable outcome, whether through a transaction or accelerated standalone execution. This review is not a sign of weakness but a proactive response to external validation of Integer's strategic position, and the market may be underestimating the probability and potential upside of a value-enhancing deal, especially given the company's leverage ratio within its target range (2.5–3.5x) and ongoing share repurchases demonstrating financial discipline.
The normalization of the electrophysiology market, while causing near-term forecast volatility, is actually a structural positive that reduces long-term uncertainty and positions Integer to benefit from sustained, predictable growth in a high-growth segment. Management's clarification that the EP market is now expected to grow in the mid-to-high teens (15%+)—down from last year's north of 20% but still firmly in double digits—indicates a maturation phase where customers have clarified their needs, reducing the risk of over- or under-forecasting due to technology uncertainty (e.g., PFA vs. RF). This stability allows Integer to better align its production and R&D efforts with actual demand, and the company's explicit statement that its EP business excluding the two new PFA products performed above market in Q1 FY26 underscores underlying strength. The headwinds from specific accessory products are viewed as temporary and order-pattern related, not indicative of lost market share or structural decline, and with Integer's broad EP portfolio and strong new product pipeline, the segment is poised to reaccelerate and contribute meaningfully to the 200 basis points above-market growth target for 2027.
Integer's disciplined financial management and proactive cost actions are creating a resilient foundation that will allow it to navigate near-term headwinds without compromising long-term growth potential, a factor the market may be overlooking in its focus on short-term EPS pressure. The company has already executed $100 million in share repurchases over two quarters, reduced interest expense via its 2025 convertible debt offering, and is implementing additional near-term cost reductions to mitigate margin pressure—all while maintaining its leverage ratio within the strategic target range (3.2x trailing adjusted EBITDA at quarter end). Crucially, management emphasized that these cost actions are designed not to damage the ability to return to market growth or achieve the 200 basis points above-market growth in 2027, signaling that R&D and critical capabilities are being preserved. This balance of near-term prudence and long-term commitment to innovation—evidenced by continued investment in new product launches across growth markets in H2 2026 and 2027—means Integer is positioning itself to emerge from the transition year with a stronger, more efficient operating model, setting the stage for accelerated profitable growth once the temporary EP normalization effects subside.

Integer Holdings Corporation's strategic review, driven by heightened market interest, presents a significant but underappreciated catalyst for shareholder value creation that extends beyond mere speculation. Management's emphasis on maintaining confidence in their standalone strategy while exploring alternatives suggests the process could yield tangible outcomes such as a premium acquisition offer from a larger medtech player seeking to enhance its CDMO capabilities, particularly in high-growth areas like electrophysiology and neurovascular. The company's strong pipeline, deep relationships with industry leaders, and proven ability to accelerate customer timelines through engineering excellence make it an attractive target, and the Board's fiduciary duty to maximize value increases the likelihood of a favorable outcome, whether through a transaction or accelerated standalone execution. This review is not a sign of weakness but a proactive response to external validation of Integer's strategic position, and the market may be underestimating the probability and potential upside of a value-enhancing deal, especially given the company's leverage ratio within its target range (2.5–3.5x) and ongoing share repurchases demonstrating financial discipline.
The normalization of the electrophysiology market, while causing near-term forecast volatility, is actually a structural positive that reduces long-term uncertainty and positions Integer to benefit from sustained, predictable growth in a high-growth segment. Management's clarification that the EP market is now expected to grow in the mid-to-high teens (15%+)—down from last year's north of 20% but still firmly in double digits—indicates a maturation phase where customers have clarified their needs, reducing the risk of over- or under-forecasting due to technology uncertainty (e.g., PFA vs. RF). This stability allows Integer to better align its production and R&D efforts with actual demand, and the company's explicit statement that its EP business excluding the two new PFA products performed above market in Q1 FY26 underscores underlying strength. The headwinds from specific accessory products are viewed as temporary and order-pattern related, not indicative of lost market share or structural decline, and with Integer's broad EP portfolio and strong new product pipeline, the segment is poised to reaccelerate and contribute meaningfully to the 200 basis points above-market growth target for 2027.
Integer's disciplined financial management and proactive cost actions are creating a resilient foundation that will allow it to navigate near-term headwinds without compromising long-term growth potential, a factor the market may be overlooking in its focus on short-term EPS pressure. The company has already executed $100 million in share repurchases over two quarters, reduced interest expense via its 2025 convertible debt offering, and is implementing additional near-term cost reductions to mitigate margin pressure—all while maintaining its leverage ratio within the strategic target range (3.2x trailing adjusted EBITDA at quarter end). Crucially, management emphasized that these cost actions are designed not to damage the ability to return to market growth or achieve the 200 basis points above-market growth in 2027, signaling that R&D and critical capabilities are being preserved. This balance of near-term prudence and long-term commitment to innovation—evidenced by continued investment in new product launches across growth markets in H2 2026 and 2027—means Integer is positioning itself to emerge from the transition year with a stronger, more efficient operating model, setting the stage for accelerated profitable growth once the temporary EP normalization effects subside.

▼ Bear case

Integer Holdings Corporation's updated 2026 outlook reveals a concerning trend of persistent forecast volatility and risk adjustment across its portfolio that suggests deeper, less transient challenges in customer demand visibility than management acknowledges, particularly beyond the electrophysiology segment. While the company attributes the recent reductions to normalization in EP and emphasizes they are not linked to the previously discussed new products, the explicit statement that further risk adjustments were applied "across the portfolio" to minimize the risk of additional forecast erosion indicates a broader loss of confidence in near-term demand predictability. This portfolio-wide prudence, coupled with the reduction in the organic growth outlook excluding the three new products from 4%-6% to 3%-4%, points to weakening fundamentals in core markets that are not being offset by the expected strength in EP or other growth areas. The reliance on customer rolling forecasts and the admission of variability in ordering patterns—even after attempts to smooth via rolling four-quarter looks—suggests that Integer's visibility into customer production plans is deteriorating, making it harder to sustain the assumed rebound to market growth in Q4 FY26 and the 200 basis points above-market growth in 2027.
The company's continued dependence on a limited number of high-impact new product launches to drive its long-term growth profile creates significant execution risk, as any delay or underperformance in these initiatives could derail the anticipated reacceleration in 2027, a vulnerability the market may be underpricing given the lack of concrete detail on pipeline timing or customer commitment levels. Management's confidence in returning to above-market growth hinges on new product launches in all growth markets in H2 2026 and 2027, yet they provided no specific updates on the status, customer uptake, or revenue contribution potential of these upcoming products during the Q&A, despite repeated probing about EP wallet share and market dynamics. The admission that the two previously discussed PFA products are not being counted for 2027 growth, combined with the focus on accessory products as the source of near-term EP headwinds, raises questions about whether the broader EP portfolio is truly positioned to capture sustained growth from the PFA shift or if Integer is overly reliant on incremental improvements rather than transformative innovations. Without clearer visibility into the readiness and market acceptance of its new product pipeline, the 2027 growth target remains aspirational and vulnerable to execution missteps.
Integer's financial leverage and capital allocation priorities, while currently within stated targets, pose a growing risk to financial flexibility if the anticipated sales recovery does not materialize, particularly given the combination of ongoing share repurchases, modest free cash flow generation, and a net debt level exceeding $1.2 billion. The company ended Q1 FY26 with $1.264 billion in net total debt and a leverage ratio of 3.2x trailing adjusted EBITDA—within the 2.5x–3.5x target range but at the higher end—and used $50 million of cash flow in the quarter to fund another share repurchase, resulting in only $1 million of free cash flow after CapEx. While management expects to generate $85–$105 million in free cash flow for FY26, this assumes a meaningful improvement in profitability and cash conversion that is not yet evident, especially with adjusted EBITDA down 7% year-over-year in Q1 and the outlook calling for only a 1%–7% full-year decline. If sales continue to underperform due to unresolved demand volatility or slower-than-expected new product ramps, the company may be forced to choose between deleveraging, sustaining repurchases, or funding growth investments—constraints that could undermine its long-term strategy and signal to the market that its financial resilience is weaker than advertised.

Integer Holdings Corporation's updated 2026 outlook reveals a concerning trend of persistent forecast volatility and risk adjustment across its portfolio that suggests deeper, less transient challenges in customer demand visibility than management acknowledges, particularly beyond the electrophysiology segment. While the company attributes the recent reductions to normalization in EP and emphasizes they are not linked to the previously discussed new products, the explicit statement that further risk adjustments were applied "across the portfolio" to minimize the risk of additional forecast erosion indicates a broader loss of confidence in near-term demand predictability. This portfolio-wide prudence, coupled with the reduction in the organic growth outlook excluding the three new products from 4%-6% to 3%-4%, points to weakening fundamentals in core markets that are not being offset by the expected strength in EP or other growth areas. The reliance on customer rolling forecasts and the admission of variability in ordering patterns—even after attempts to smooth via rolling four-quarter looks—suggests that Integer's visibility into customer production plans is deteriorating, making it harder to sustain the assumed rebound to market growth in Q4 FY26 and the 200 basis points above-market growth in 2027.
The company's continued dependence on a limited number of high-impact new product launches to drive its long-term growth profile creates significant execution risk, as any delay or underperformance in these initiatives could derail the anticipated reacceleration in 2027, a vulnerability the market may be underpricing given the lack of concrete detail on pipeline timing or customer commitment levels. Management's confidence in returning to above-market growth hinges on new product launches in all growth markets in H2 2026 and 2027, yet they provided no specific updates on the status, customer uptake, or revenue contribution potential of these upcoming products during the Q&A, despite repeated probing about EP wallet share and market dynamics. The admission that the two previously discussed PFA products are not being counted for 2027 growth, combined with the focus on accessory products as the source of near-term EP headwinds, raises questions about whether the broader EP portfolio is truly positioned to capture sustained growth from the PFA shift or if Integer is overly reliant on incremental improvements rather than transformative innovations. Without clearer visibility into the readiness and market acceptance of its new product pipeline, the 2027 growth target remains aspirational and vulnerable to execution missteps.
Integer's financial leverage and capital allocation priorities, while currently within stated targets, pose a growing risk to financial flexibility if the anticipated sales recovery does not materialize, particularly given the combination of ongoing share repurchases, modest free cash flow generation, and a net debt level exceeding $1.2 billion. The company ended Q1 FY26 with $1.264 billion in net total debt and a leverage ratio of 3.2x trailing adjusted EBITDA—within the 2.5x–3.5x target range but at the higher end—and used $50 million of cash flow in the quarter to fund another share repurchase, resulting in only $1 million of free cash flow after CapEx. While management expects to generate $85–$105 million in free cash flow for FY26, this assumes a meaningful improvement in profitability and cash conversion that is not yet evident, especially with adjusted EBITDA down 7% year-over-year in Q1 and the outlook calling for only a 1%–7% full-year decline. If sales continue to underperform due to unresolved demand volatility or slower-than-expected new product ramps, the company may be forced to choose between deleveraging, sustaining repurchases, or funding growth investments—constraints that could undermine its long-term strategy and signal to the market that its financial resilience is weaker than advertised.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password